179 related articles for article (PubMed ID: 29342057)
1. Audiologic Natural History of Small Volume Cochleovestibular Schwannomas in Neurofibromatosis Type 2.
deTorres AT; Brewer CC; Zalewski CK; King KA; Walker R; Scott GC; Asthagiri AR; Chittiboina P; Kim HJ
Otol Neurotol; 2018 Mar; 39(3):357-364. PubMed ID: 29342057
[TBL] [Abstract][Full Text] [Related]
2. Audiovestibular Characteristics of Small Cochleovestibular Schwannomas in Neurofibromatosis Type 2.
Holliday MA; Kim HJ; Zalewski CK; Wafa T; Dewan R; King KA; Brewer CC; Butman JA; Asthagiri AR
Otolaryngol Head Neck Surg; 2014 Jul; 151(1):117-24. PubMed ID: 24718755
[TBL] [Abstract][Full Text] [Related]
3. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
Fisher LM; Doherty JK; Lev MH; Slattery WH
Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
Plotkin SR; Halpin C; McKenna MJ; Loeffler JS; Batchelor TT; Barker FG
Otol Neurotol; 2010 Sep; 31(7):1135-43. PubMed ID: 20736812
[TBL] [Abstract][Full Text] [Related]
5. Hearing Loss Progresses Faster in Patients With Growing Intracanalicular Vestibular Schwannomas.
van Linge A; Borsboom GJ; Wieringa MH; Goedegebure A
Otol Neurotol; 2016 Oct; 37(9):1442-8. PubMed ID: 27579837
[TBL] [Abstract][Full Text] [Related]
6. Neurofibromatosis 2 invasion of the internal auditory canal wall: clinical significance.
Doherty J; Go JL; Linthicum FH
Otol Neurotol; 2014 Oct; 35(9):1662-8. PubMed ID: 25118583
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
[TBL] [Abstract][Full Text] [Related]
8. Progress of hearing loss in neurofibromatosis type 2: implications for future management.
Kontorinis G; Nichani J; Freeman SR; Rutherford SA; Mills S; King AT; Mawman D; Huson S; O'Driscoll M; Gareth Evans D; Lloyd SK
Eur Arch Otorhinolaryngol; 2015 Nov; 272(11):3143-50. PubMed ID: 25294053
[TBL] [Abstract][Full Text] [Related]
9. Pediatric cerebellopontine angle and internal auditory canal tumors: clinical article.
Holman MA; Schmitt WR; Carlson ML; Driscoll CL; Beatty CW; Link MJ
J Neurosurg Pediatr; 2013 Oct; 12(4):317-24. PubMed ID: 23909617
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab for Hearing Preservation in Neurofibromatosis Type 2: Emphasis on Patient-Reported Outcomes and Toxicities.
Sverak P; Adams ME; Haines SJ; Levine SC; Nascene D; Sommer K; Dusenbery K; Huang TC; Moertel C
Otolaryngol Head Neck Surg; 2019 Mar; 160(3):526-532. PubMed ID: 30373466
[TBL] [Abstract][Full Text] [Related]
11. Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients.
Plotkin SR; Merker VL; Muzikansky A; Barker FG; Slattery W
Otol Neurotol; 2014 Jan; 35(1):e50-6. PubMed ID: 24335938
[TBL] [Abstract][Full Text] [Related]
12. Hearing changes after diagnosis in neurofibromatosis type 2.
Masuda A; Fisher LM; Oppenheimer ML; Iqbal Z; Slattery WH;
Otol Neurotol; 2004 Mar; 25(2):150-4. PubMed ID: 15021775
[TBL] [Abstract][Full Text] [Related]
13. Surgical management of vestibular schwannomas and hearing rehabilitation in neurofibromatosis type 2.
Tysome JR; Macfarlane R; Durie-Gair J; Donnelly N; Mannion R; Knight R; Harris F; Vanat ZH; Tam YC; Burton K; Hensiek A; Raymond FL; Moffat DA; Axon PR
Otol Neurotol; 2012 Apr; 33(3):466-72. PubMed ID: 22334163
[TBL] [Abstract][Full Text] [Related]
14. Linear accelerator-based stereotactic radiosurgery for bilateral vestibular schwannomas in patients with neurofibromatosis type 2.
Meijer OW; Vandertop WP; Lagerwaard FJ; Slotman BJ
Neurosurgery; 2008 May; 62(5 Suppl):A37-42; discussion A42-3. PubMed ID: 18580779
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
Mautner VF; Nguyen R; Kutta H; Fuensterer C; Bokemeyer C; Hagel C; Friedrich RE; Panse J
Neuro Oncol; 2010 Jan; 12(1):14-8. PubMed ID: 20150363
[TBL] [Abstract][Full Text] [Related]
16. The Size of Internal Auditory Canal Diverticula Is Unrelated to Degree of Hearing Loss.
Muelleman TJ; Pippin K; Shew M; Villwock M; Lin J; Quesnel AM; Ledbetter L; Staecker H
Laryngoscope; 2020 Apr; 130(4):1011-1015. PubMed ID: 31233221
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of hearing loss in neurofibromatosis type 2.
Asthagiri AR; Vasquez RA; Butman JA; Wu T; Morgan K; Brewer CC; King K; Zalewski C; Kim HJ; Lonser RR
PLoS One; 2012; 7(9):e46132. PubMed ID: 23049959
[TBL] [Abstract][Full Text] [Related]
18. Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2.
Huang V; Bergner AL; Halpin C; Merker VL; Sheridan MR; Widemann BC; Blakeley JO; Plotkin SR
Otol Neurotol; 2018 Jun; 39(5):632-638. PubMed ID: 29649040
[TBL] [Abstract][Full Text] [Related]
19. Tumor growth and audiometric change in vestibular schwannomas managed conservatively.
Massick DD; Welling DB; Dodson EE; Scholfield M; Nagaraja HN; Schmalbrock P; Chakeres DW
Laryngoscope; 2000 Nov; 110(11):1843-9. PubMed ID: 11081597
[TBL] [Abstract][Full Text] [Related]
20. Vestibular Schwannomas: Do Linear and Volumetric Parameters on MRI Correlate With Hearing Loss?
Bathla G; Case BM; Berbaum K; Hansen MR; Policeni B
Otol Neurotol; 2016 Sep; 37(8):1168-73. PubMed ID: 27466888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
